ImmuneRegen BioSciences Inc announces partnership with Bachem Inc, for manufacturing of Homspera.

ImmuneRegen BioSciences Inc (ImmuneRegen) announced an agreement with Bachem Inc, enabling Bachem to be the primary manufacturer of ImmuneRegen's Homspera drug substance. Homspera is a peptide analog of the endogenous neurokinin Substance P, and is actively being developed by ImmuneRegen for a number of therapeutic indications including cancer, infectious diseases, pulmonary diseases such as Idiopathic Pulmonary Fibrosis, and wound healing. Under the agreement Bachem will produce the active pharmaceutical ingredient Homspera under current Good …